Cameron Academy Author2024-12-01T19:04:27-05:00Cameron Academy Author2024-12-01T19:04:27-05:00December 1, 2024|
CRISPR technology has become the frontrunner in genome editing, surpassing earlier methods like zinc finger nucleases and transcription activator-like effector nucleases. The recent FDA approval of the CRISPR-Cas9 drug, exa-cel, marks a significant milestone particularly for treating sickle cell disease and transfusion-dependent beta thalassemia.